Epigenetic regulation of interleukin 6 by histone acetylation in macrophages and its role in paraquat-induced pulmonary fibrosis

Frontiers in Immunology

Volumn 7, Issue JAN, 2017, Pages

  Hu, Lingli ^a   Yu, Yanfang ^a   Huang, Huijie ^a   Fan, Hanting ^a   Hu, Li ^a   Yin, Caiyong ^a   Li, Kai ^a   Fulton, David J R ^b,c   Chen, Feng ^a,b  

^a NANJING MEDICAL UNIVERSITY   (China)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c AUGUSTA UNIVERSITY   (United States)

Author keywords

Epigenetics; Forensic toxicology; Histone acetylation; IL 6; Paraquat; Pulmonary fibrosis

Indexed keywords

HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE INHIBITOR; INTERLEUKIN 6; PARAQUAT;

ANIMAL TISSUE; ARTICLE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA SEQUENCE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE SEQUENCE; HEK293 CELL LINE; HISTONE ACETYLATION; IMMUNOHISTOCHEMISTRY; LUNG FIBROSIS; MACROPHAGE; MALE; MOUSE; NONHUMAN; PNEUMONIA; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 85012081865     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2016.00696     Document Type: Article

References (66)

1. Crystal RG, Bitterman PB, Mossman B, Schwarz MI, Sheppard D, Almasy L, et al. Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group. Am J Respir Crit Care Med (2002) 166(2):236-46. doi:10.1164/rccm.2201069.
2. Haston CK, Tomko TG, Godin N, KerckhoffL, Hallett MT. Murine candidate bleomycin induced pulmonary fibrosis susceptibility genes identified by gene expression and sequence analysis of linkage regions. J Med Genet (2005) 42(6):464-73. doi:10.1136/jmg.2004.027938.
3. King TE, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet (2011) 378(9807):1949-61. doi:10.1016/S0140-6736(11)60052-4.
4. Wilson MS, Wynn TA. Pulmonary fibrosis: pathogenesis, etiology and regulation. Mucosal Immunol (2009) 2(2):103-21. doi:10.1038/mi.2008.85.
5. Yang IV, Schwartz DA. Epigenetics of idiopathic pulmonary fibrosis. Transl Res (2015) 165(1):48-60. doi:10.1016/j.trsl.2014.03.011.
6. Piera-Velazquez S, Mendoza FA, Jimenez SA. Endothelial to mesenchymal transition (EndoMT) in the pathogenesis of human fibrotic diseases. J Clin Med (2016) 5(4):E45. doi:10.3390/jcm5040045.
7. Han YY, Shen P, Chang WX. Involvement of epithelial-to-mesenchymal transition and associated transforming growth factor-beta/Smad signaling in paraquat-induced pulmonary fibrosis. Mol Med Rep (2015) 12(6):7979-84. doi:10.3892/mmr.2015.4454.
8. Rosenbloom J, Castro SV, Jimenez SA. Narrative review: fibrotic diseases: cellular and molecular mechanisms and novel therapies. Ann Intern Med (2010) 152(3):159-66. doi:10.7326/0003-4819-152-3-201002020-00007.
9. Zeisberg M, Kalluri R. The role of epithelial-to-mesenchymal transition in renal fibrosis. J Mol Med (Berl) (2004) 82(3):175-81. doi:10.1007/s00109-003-0517-9.
10. Wu CY, Tsai YP, Wu MZ, Teng SC, Wu KJ. Epigenetic reprogramming and post-transcriptional regulation during the epithelial-mesenchymal transition. Trends Genet (2012) 28(9):454-63. doi:10.1016/j.tig.2012.05.005.
11. Acloque H, Adams MS, Fishwick K, Bronner-Fraser M, Nieto MA. Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease. J Clin Invest (2009) 119(6):1438-49. doi:10.1172/JCI38019.
12. Yamada A, Aki T, Unuma K, Funakoshi T, Uemura K. Paraquat induces epithelial-mesenchymal transition-like cellular response resulting in fibrogenesis and the prevention of apoptosis in human pulmonary epithelial cells. PLoS One (2015) 10(3):e0120192. doi:10.1371/journal.pone.0120192.
13. Ho LJ, Luo SF, Lai JH. Biological effects of interleukin-6: clinical applications in autoimmune diseases and cancers. Biochem Pharmacol (2015) 97(1):16-26. doi:10.1016/j.bcp.2015.06.009.
14. Gabay C. Interleukin-6 and chronic inflammation. Arthritis Res Ther (2006) 8(Suppl 2):S3. doi:10.1186/ar1908.
15. Fayad L, Keating MJ, Reuben JM, O'Brien S, Lee BN, Lerner S, et al. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood (2001) 97(1):256-63. doi:10.1182/blood. V97.1.256.
16. Banerjee I, Fuseler JW, Intwala AR, Baudino TA. IL-6 loss causes ventricular dysfunction, fibrosis, reduced capillary density, and dramatically alters the cell populations of the developing and adult heart. Am J Physiol Heart Circ Physiol (2009) 296(5):H1694-704. doi:10.1152/ajpheart.00908.2008.
17. Knight D, Mutsaers SE, Prele CM. STAT3 in tissue fibrosis: is there a role in the lung? Pulm Pharmacol Ther (2011) 24(2):193-8. doi:10.1016/j.pupt.2010.10.005.
18. Le TT, Karmouty-Quintana H, MelicoffE, Le TT, Weng T, Chen NY, et al. Blockade of IL-6 trans signaling attenuates pulmonary fibrosis. J Immunol (2014) 193(7):3755-68. doi:10.4049/jimmunol.1302470.
19. Tomita M, Okuyama T, Katsuyama H, Miura Y, Nishimura Y, Hidaka K, et al. Mouse model of paraquat-poisoned lungs and its gene expression profile. Toxicology (2007) 231(2-3):200-9. doi:10.1016/j.tox.2006.12.005.
20. Pedroza M, Le TT, Lewis K, Karmouty-Quintana H, To S, George AT, et al. STAT-3 contributes to pulmonary fibrosis through epithelial injury and fibroblast-myofibroblast differentiation. FASEB J (2016) 30(1):129-40. doi:10.1096/fj.15-273953.
21. O'Reilly S, Ciechomska M, Cant R, van Laar JM. Interleukin-6 (IL-6) trans signaling drives a STAT3-dependent pathway that leads to hyperactive transforming growth factor-beta (TGF-beta) signaling promoting SMAD3 activation and fibrosis via gremlin protein. J Biol Chem (2014) 289(14):9952-60. doi:10.1074/jbc. M113.545822.
22. Fielding CA, Jones GW, McLoughlin RM, McLeod L, Hammond VJ, Uceda J, et al. Interleukin-6 signaling drives fibrosis in unresolved inflammation. Immunity (2014) 40(1):40-50. doi:10.1016/j.immuni.2013.10.022.
23. Cui W, Zhang H, Liu ZL. Interleukin-6 receptor blockade suppresses subretinal fibrosis in a mouse model. Int J Ophthalmol (2014) 7(2):194-7. doi:10.3980/j.issn.2222-3959.2014.02.02.
24. Hull EE, Montgomery MR, Leyva KJ. HDAC inhibitors as epigenetic regulators of the immune system: impacts on cancer therapy and inflammatory diseases. Biomed Res Int (2016) 2016:8797206. doi:10.1155/2016/8797206.
25. Barnes PJ. Reduced histone deacetylase in COPD: clinical implications. Chest (2006) 129(1):151-5. doi:10.1378/chest.129.1.151.
26. Coward WR, Watts K, Feghali-Bostwick CA, Knox A, Pang L. Defective histone acetylation is responsible for the diminished expression of cyclooxygenase 2 in idiopathic pulmonary fibrosis. Mol Cell Biol (2009) 29(15):4325-39. doi:10.1128/MCB.01776-08.
27. Ito K, Ito M, Elliott WM, Cosio B, Caramori G, Kon OM, et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med (2005) 352(19):1967-76. doi:10.1056/NEJMoa041892.
28. Ota C, Yamada M, Fujino N, Motohashi H, Tando Y, Takei Y, et al. Histone deacetylase inhibitor restores surfactant protein-C expression in alveolar-epithelial type II cells and attenuates bleomycin-induced pulmonary fibrosis in vivo. Exp Lung Res (2015) 41(8):422-34. doi:10.3109/01902148.2015.1060275.
29. Royce SG, Moodley Y, Samuel CS. Novel therapeutic strategies for lung disorders associated with airway remodelling and fibrosis. Pharmacol Ther (2014) 141(3):250-60. doi:10.1016/j.pharmthera.2013.10.008.
30. Bishton MJ, Johnstone RW, Dickinson M, Harrison S, Prince HM. Overview of histone deacetylase inhibitors in haematological malignancies. Pharmaceuticals (Basel) (2010) 3(8):2674-88. doi:10.3390/ph3082674.
31. Luo Y, Wang Y, Shu Y, Lu Q, Xiao R. Epigenetic mechanisms: an emerging role in pathogenesis and its therapeutic potential in systemic sclerosis. Int J Biochem Cell Biol (2015) 67:92-100. doi:10.1016/j.biocel.2015.05.023.
32. Gregoretti I, Lee Y-M, Goodson HV. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol (2004) 338(1):17-31. doi:10.1016/j.jmb.2004.02.006.
33. Rafehi H, Balcerczyk A, Lunke S, Kaspi A, Ziemann M, Kn H, et al. Vascular histone deacetylation by pharmacological HDAC inhibition. Genome Res (2014) 24(8):1271-84. doi:10.1101/gr.168781.113.
34. Glaser KB, Staver MJ, Waring JF, Stender J, Ulrich RG, Davidsen SK. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther (2003) 2(2):151-63.
35. Wu X, Scott DA, Kriz AJ, Chiu AC, Hsu PD, Dadon DB, et al. Genome-wide binding of the CRISPR endonuclease Cas9 in mammalian cells. Nat Biotechnol (2014) 32(7):670-6. doi:10.1038/nbt.2889.
36. Giménez CA, Ielpi M, Mutto A, Grosembacher L, Argibay P, Pereyra-Bonnet F. CRISPR-on system for the activation of the endogenous human INS gene. Gene Ther (2016) 23(6):543-7. doi:10.1038/gt.2016.28.
37. Konermann S, Brigham MD, Trevino AE, Joung J, Abudayyeh OO, Barcena C, et al. Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature (2015) 517(7536):583-8. doi:10.1038/nature14136.
38. Shao X, Li M, Luo C, Wang YY, Lu YY, Feng S, et al. Effects of rapamycin against paraquat-induced pulmonary fibrosis in mice. J Zhejiang Univ Sci B (2015) 16(1):52-61. doi:10.1631/jzus. B1400229.
39. Amirshahrokhi K, Bohlooli S. Effect of methylsulfonylmethane on paraquat-induced acute lung and liver injury in mice. Inflammation (2013) 36(5):1111-21. doi:10.1007/s10753-013-9645-8.
40. Mees ST, Toellner S, Marx K, Faendrich F, Kallen KJ, Schroeder J, et al. Inhibition of interleukin-6-transsignaling via gp130-Fc in hemorrhagic shock and sepsis. J Surg Res (2009) 157(2):235-42. doi:10.1016/j.jss.2008.08.035.
41. Mannaerts I, Nuytten NR, Rogiers V, Vanderkerken K, van Grunsven LA, Geerts A. Chronic administration of valproic acid inhibits activation of mouse hepatic stellate cells in vitro and in vivo. Hepatology (2010) 51(2):603-14. doi:10.1002/hep.23334.
42. Peng C, Zhang W, Zhao W, Zhu J, Huang X, Tian J. Alcohol-induced histone H3K9 hyperacetylation and cardiac hypertrophy are reversed by a histone acetylases inhibitor anacardic acid in developing murine hearts. Biochimie (2015) 113:1-9. doi:10.1016/j.biochi.2015.03.012.
43. Peng C, Zhu J, Sun HC, Huang XP, Zhao WA, Zheng M, et al. Inhibition of histone H3K9 acetylation by anacardic acid can correct the over-expression of Gata4 in the hearts of fetal mice exposed to alcohol during pregnancy. PLoS One (2014) 9(8):e104135. doi:10.1371/journal.pone.0104135.
44. Xia Q, Sung J, Chowdhury W, Chen CL, Höti N, Shabbeer S, et al. Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo. Cancer Res (2006) 66(14):7237-44. doi:10.1158/0008-5472.CAN-05-0487.
45. Gnanaprakasam JN, Estrada-Muniz E, Vega L. The anacardic 6-pentadecyl salicylic acid induces macrophage activation via the phosphorylation of ERK1/2, JNK, P38 kinases and NF-kappaB. Int Immunopharmacol (2015) 29(2):808-17. doi:10.1016/j.intimp.2015.08.038.
46. Fernando MR, Reyes JL, Iannuzzi J, Leung G, McKay DM. The pro-inflammatory cytokine, interleukin-6, enhances the polarization of alternatively activated macrophages. PLoS One (2014) 9(4):e94188. doi:10.1371/journal.pone.0094188.
47. Van Beneden K, Geers C, Pauwels M, Mannaerts I, Wissing KM, Van den Branden C, et al. Comparison of trichostatin A and valproic acid treatment regimens in a mouse model of kidney fibrosis. Toxicol Appl Pharmacol (2013) 271(2):276-84. doi:10.1016/j.taap.2013.05.013.
48. Korfei M, Skwarna S, Henneke I, MacKenzie B, Klymenko O, Saito S, et al. Aberrant expression and activity of histone deacetylases in sporadic idiopathic pulmonary fibrosis. Thorax (2015) 70(11):1022-32. doi:10.1136/thoraxjnl-2014-206411.
49. Schuetze KB, McKinsey TA, Long CS. Targeting cardiac fibroblasts to treat fibrosis of the heart: focus on HDACs. J Mol Cell Cardiol (2014) 70:100-7. doi:10.1016/j.yjmcc.2014.02.015.
50. Fattori E, Cappelletti M, Costa P, Sellitto C, Cantoni L, Carelli M, et al. Defective inflammatory response in interleukin 6-deficient mice. J Exp Med (1994) 180(4):1243-50. doi:10.1084/jem.180.4.1243.
51. Jones SA, Horiuchi S, Topley N, Yamamoto N, Fuller GM. The soluble interleukin 6 receptor: mechanisms of production and implications in disease. FASEB J (2001) 5(1):43-58. doi:10.1096/fj.99-1003rev.
52. Pechkovsky DV, Prêle CM, Wong J, Hogaboam CM, McAnulty RJ, Laurent GJ, et al. STAT3-mediated signaling dysregulates lung fibroblast-myofibroblast activation and differentiation in UIP/IPF. Am J Pathol (2012) 180(4):1398-412. doi:10.1016/j.ajpath.2011.12.022.
53. Kobayashi T, Tanaka K, Fujita T, Umezawa H, Amano H, Yoshioka K, et al. Bidirectional role of IL-6 signal in pathogenesis of lung fibrosis. Respir Res (2015) 16:99. doi:10.1186/s12931-015-0261-z.
54. Moodley YP, Scaffidi AK, Misso NL, Keerthisingam C, McAnulty RJ, Laurent GJ, et al. Fibroblasts isolated from normal lungs and those with idiopathic pulmonary fibrosis differ in interleukin-6/gp130-mediated cell signaling and proliferation. Am J Pathol (2003) 163(1):345-54. doi:10.1016/S0002-9440(10)63658-9.
55. Baecher-Allan CM, Barth RK. PCR analysis of cytokine induction profiles associated with mouse strain variation in susceptibility to pulmonary fibrosis. Reg Immunol (1993) 5(3-4):207-17.
56. O'Reilly S, Cant R, Ciechomska M, van Laar JM. Interleukin-6: a new therapeutic target in systemic sclerosis? Clin Transl Immunology (2013) 2(4):e4. doi:10.1038/cti.2013.2.
57. Desallais L, Avouac J, Fréchet M, Elhai M, Ratsimandresy R, Montes M, et al. Targeting IL-6 by both passive or active immunization strategies prevents bleomycin-induced skin fibrosis. Arthritis Res Ther (2014) 16(4):R157. doi:10.1186/ar4672.
58. Hashimoto-Kataoka T, Hosen N, Sonobe T, Arita Y, Yasui T, Masaki T, et al. Interleukin-6/interleukin-21 signaling axis is critical in the pathogenesis of pulmonary arterial hypertension. Proc Natl Acad Sci U S A (2015) 112(20):E2677-86. doi:10.1073/pnas.1424774112.
59. Zhang Z, Zhang R. Epigenetics in autoimmune diseases: pathogenesis and prospects for therapy. Autoimmun Rev (2015) 14(10):854-63. doi:10.1016/j.autrev.2015.05.008.
60. Nural-Guvener H, Zakharova L, Feehery L, Sljukic S, Gaballa M. Anti-fibrotic effects of class I HDAC inhibitor, mocetinostat is associated with IL-6/Stat3 signaling in ischemic heart failure. Int J Mol Sci (2015) 16(5):11482-99. doi:10.3390/ijms160511482.
61. Hartman H, Wetterholm E, Thorlacius H, Regnér S. Histone deacetylase regulates trypsin activation, inflammation, and tissue damage in acute pancreatitis in mice. Dig Dis Sci (2015) 60(5):1284-9. doi:10.1007/s10620-014-3474-y.
62. Pang M, Zhuang S. Histone deacetylase: a potential therapeutic target for fibrotic disorders. J Pharmacol Exp Ther (2010) 335(2):266-72. doi:10.1124/jpet.110.168385.
63. Guo W, Shan B, Klingsberg RC, Qin X, Lasky JA. Abrogation of TGF-beta1-induced fibroblast-myofibroblast differentiation by histone deacetylase inhibition. Am J Physiol Lung Cell Mol Physiol (2009) 297(5):L864-70. doi:10.1152/ajplung.00128.2009.
64. Barnes PJ, Adcock IM, Ito K. Histone acetylation and deacetylation: importance in inflammatory lung diseases. Eur Respir J (2005) 25(3):552-63. doi:10.1183/09031936.05.00117504.
65. Bogaard HJ, Mizuno S, Hussaini AA, Toldo S, Abbate A, Kraskauskas D, et al. Suppression of histone deacetylases worsens right ventricular dysfunction after pulmonary artery banding in rats. Am J Respir Crit Care Med (2011) 183(10):1402-10. doi:10.1164/rccm.201007-1106OC.
66. Chan HM, La Thangue NB. p300/CBP proteins: HATs for transcriptional bridges and scaffolds. J Cell Sci (2001) 114(13):2363-73.